Therapeutics, Targets, and Chemical Biology

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer

Yi-Hsin Hsu1, Jun Yao1, Li-Chuan Chan1,2, Ting-Jung Wu1,3, Jennifer L. Hsu1,4,5, Yuede-Fu Fang1,6, Yongkun Wei1, Yun Wu7, Wen-Chien Huang8, Chien-Liang Liu9, Yuan-Ching Chang8, Ming-Yang Wang1,9, Chia-Wei Li1, Jia Shen1,2, Mei-Kuang Chen2, Aysegul A. Sahin7, Anil Sood2,10, Gordon B. Mills2,11, Dihua Yu1,2, Gabriel N. Hortobagyi12, and Mien-Chie Hung1,2,4,5

Abstract

Triple-negative breast cancer (TNBC) is a highly heterogeneous and recurrent subtype of breast cancer that lacks an effective targeted therapy. To identify candidate therapeutic targets, we profiled global gene expression in TNBC and breast tumor-initiating cells with a patient survival dataset. Eight TNBC-related kinases were found to be overexpressed in TNBC cells with stem-like properties. Among them, expression of PKC-α, MET, and CDK6 correlated with poorer survival outcomes. In cases coexpressing two of these three kinases, survival rates were lower than in cases where only one of these kinases was expressed. In functional tests, two-drug combinations targeting these three kinases inhibited TNBC cell proliferation and tumorigenic potential in a cooperative manner. A combination of PKC-α-MET inhibitors also attenuated tumor growth in a cooperative manner in vivo. Our findings define three kinases critical for TNBC growth and offer a preclinical rationale for their candidacy as effective therapeutic targets in treating TNBC. Cancer Res; 74(17); 1–14. ©2014 AACR.

Introduction

Breast cancers are typically classified into several subtypes: Luminal A and B subtypes of breast cancer that correspond to pathologic estrogen receptor (ER)-positive tumors, the HER2 subtype that corresponds to HER2-overexpressing tumors, and triple-negative/basal-like breast cancer (TNBC/BLBC). BLBC makes up about 15% to 20% of breast cancers. Recent studies using clinical samples indicate that BLBC shares more than 80% similarity with TNBC, which is negative for ER, progesterone receptor (PR), and HER2 expression (1). In addition, two major subgroups of TNBC characterized on the basis of gene ontologies and differential gene expression profile have been reported: basal-like TNBC driven by genes enriched in cell cycle, cell division, and DNA damage response; and mesenchymal-like driven by genes involved in cell motility, cell differentiation, and growth factor pathways (2). These findings indicate that TNBCs are highly heterogeneous. Although subtyping allows for better prediction of the response of each subtype to specific molecular targets, the therapeutic benefits in clinical trial are still unclear. Here, we will use TNBC as a general term to broadly represent the TNBC/BLBC subtype.

Patients with TNBC initially respond to conventional chemotherapy, but the disease frequently relapses and leads to worse outcome than patients with hormone receptor-positive subtypes (3). The low survival rate of patients with TNBC is also due to high metastasis rates and lack of effective treatment after a relapse (4). Currently, no effective targeted therapies are available for patients with TNBC because of TNBC's lack of expression of hormone receptors and HER2 amplification (1, 5).

A cancer stem cell (CSC) or tumor-initiating cell (TIC) hypothesis has been proposed to account for treatment failure and recurrence in patients with TNBC (6). Breast TICs (BTIC) make up a small subpopulation of cells inside tumors that are resistant to conventional therapy and are capable of reinitiating tumor growth after treatment (7–9); these cells can be enriched by flow cytometry using specific cell-surface markers such as CD44+/CD24low (10) and ALDH1high (11). Accumulating evidence suggests that BTICs are responsible for tumor initiation, progression, and drug resistance (12, 13). Residual breast tumor cells that survive after conventional

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Author: Mien-Chie Hung, Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. ©2014 American Association for Cancer Research.

www.aacrjournals.org

Published OnlineFirst June 26, 2014; DOI: 10.1158/0008-5472.CAN-14-0584

Received May 1, 2017. © 2014 American Association for Cancer Research.
treatment may contain a high proportion of cells with both tumor-initiating and mesenchymal features (7, 14). In line with these BTIC features, TNBC also exhibits stem cell signatures and epithelial–mesenchymal transition characteristics with high expression of mesenchymal markers (1, 15). We hypothesized that BTICs and disease recurrence may activate common pathways and contribute to the resistance of TNBC.

On the basis of the Cancer Genome Atlas (TCGA) analysis, the mutation rates of genes other than TP53 (80%) or PIK3CA (9%) are less than 5% in TNBC (16). However, there is no effective way to address loss/mutations of p53 in the clinic at this moment, and the effects of the PI3K pathway inhibitors in clinical trials are yet to be seen (17–20). miRNA-regulated gene expression has been implicated in cancer progression (21), suggesting that in addition to DNA alteration (mutation or amplification), miRNA regulation may contribute to TNBC progression by turning on certain oncogenic gene expression. To find novel other therapeutic targets, we performed an unbiased two-stage bioinformatics analysis (cell and patient based) of TNBC/BTIC (mRNA and miRNA) databases and patient survival data to identify key oncogenic molecules in TNBC, with a particular focus on those targeted by drugs that are currently in oncology clinical trials. Through this analysis, we identified eight kinases linking TNBC and CSCs.

Materials and Methods

Drugs

Crizotinib was purchased from LC Laboratories (C-7900), safingol from Matreya LLC (1807) or Sigma (D4681), L-threohydrophosphinosine from Santa Cruz Biotechnology (CAS 73938-69-9), and PD-0332991 from Sigma (PZ0199).

Cell lines

MDA-MB-231, Hs578T, BT549, MDA-MB-468, T47D, MCF7, and SK-BR-3 cells were grown in DMEM-F12 medium (Caisson Laboratories, Inc.) supplemented with 10% FBS, penicillin (50 U/mL), and streptomycin (50 U/mL). Immortal normal mammary epithelial cells (MCF10A) were cultured in DMEM-F12 medium supplemented with 5% horse serum, penicillin (50 U/mL), streptomycin (50 U/mL), EGF (20 ng/mL), insulin (10 µg/mL), cholera toxin (1 ng/mL), and hydrocortisone. BT20 cells were grown in DMEM medium (Caisson Laboratories, Inc.) supplemented with 10% FBS, penicillin (50 U/mL), streptomycin (50 U/mL), and nonessential amino acids. Cell lines were validated by short tandem repeat (STR) DNA fingerprinting using the AmpFLSTR Identifier Kit according to the manufacturer's instructions (Applied Biosystems catalog no. 4322288). The STR profiles were compared with known American Type Culture Collection fingerprints (ATCC.org) and with data in the Cell Line Integrated Mammalian Authentication database version 0.1.200808 (22). The STR profiles matched known DNA fingerprints or were unique.

Analysis of public gene expression data

The following databases were used to compare TNBC data with non-TNBC data: E-MTAB-327 (miRNA expression profiling by array of NCI-60 human cancer cell lines), GSE25037 (miRNA expression profiling in CD44+/CD24− low and non-CD44+/CD24− low human mammary epithelial cell populations), Cancer Cell Line Encyclopedia (CCLE) data on breast cancer cell mRNA expression (23), and GSE7513 (human breast tumor sample data were sorted to select cells that were CD44+/CD24− low). The log2 ratio of TNBC versus non-TNBC data from public microarray databases was determined using NetWalk software (24). Gene expression profiles, pathways, and cross-talk were analyzed with the Ingenuity Pathway Analysis System.

Hierarchical clustering

Clustering was analyzed with an integrated pair of programs, Cluster and TreeView (25), for analyzing and visualizing the results of complex microarray experiments, and the median adjusted values were used to create expression files. The hierarchical clustering algorithm used is based closely on the average-linkage method of Sokal and colleagues (26). For any set of TNBC-related kinases, an upper-diagonal similarity matrix was computed by using average-linkage clustering, which contained similar scores for all pairs of genes. This algorithm was determined by computing a dendrogram assembling all elements into a single tree, as described by Eisen and colleagues (25). The software application of this algorithm was obtained from M.B. Eisen Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, CA (25).

Display

The heatmap was represented graphically by coloring each cell on the basis of the measured fluorescence ratio. Log ratios of 0 (a ratio of 1.0 indicates that the genes are unchanged) were colored in black, positive log ratios were colored in red, and negative log ratios were colored in green (with darker colors corresponding to higher ratios).

qRT-PCR

Total RNAs from different breast cancer cells were extracted by using the RNeasy Kit (Qiagen). RNAs were reverse transcribed by using the Superscript II Kit (Invitrogen). RT-PCR was then performed using the iCycler (Bio-Rad). RNA levels were quantitated and normalized to an adjusted values were used to create expression

OF2 Cancer Res; 74(17) September 1, 2014 Cancer Research
**PIK3CD**: 5′-TGCCAAACCACCTCCATTCTC-3′ and 5′-CATCCTGGTGGCGTGAAAAGC-3′.

**Western blotting**

Western blotting was carried out as described previously (27) with anti-LYN (Santa Cruz Biotechnology), anti-MAP4K4 (GeneTex), anti-FYN (Cell Signaling Technology), anti-MET (Cell Signaling Technology), anti-RPS6KA3 (Cell Signaling Technology), anti-PKRCA (BD Biosciences), anti-CDK6 (Abcam), and anti-PIK3CD (GeneTex) antibodies. The membranes were stripped and reprobed with an anti-α-tubulin mouse monoclonal antibody (Sigma) as a loading control.

**Patient overall survival analysis**

The NKI-295 database (28) was used for analysis of TNBC-related gene expression and overall survival. A gene expression level within the first quartile was defined as positive. Survival curves were estimated by the Kaplan–Meier method, and survival rates in different groups were compared by the log-rank test. The data were analyzed using statistical software SPSS version 17.0. A P value ≤ 0.05 was defined as statistically significant.

**Cell viability assay**

Cells were seeded in 96-well plates at an initial density of 2 × 10³ per well. At each time point, cells were stained with 100 μL of sterile MTT (0.5 mg/mL; Sigma) for 2 hours at 37 °C, followed by removal of the culture medium and addition of 100 μL of dimethyl sulfoxide. Absorbance was measured at 570 nm, using 655 nm as the reference wavelength. All experiments were carried out in triplicate.

**Anchorage-independent colony growth**

Two thousand cells were trypsinized and suspended in 2 mL of complete medium plus 0.3% agar (Sigma). The cell/agar mixture was plated on top of a layer of 1% agar in complete medium. After 21 days, viable colonies that were larger than 0.1 mm in diameter were counted using ImageJ software. Experiments were carried out for each cell line in triplicate.

**Colonies formation assay**

Cells were plated in 6-well plates (2–5 × 10⁵ cells/well) and cultured for 10 days. Colonies were stained with 1% crystal violet for 10 minutes after fixation with 4% paraformaldehyde for 5 minutes.

**Dual-drug combination assay**

Breast cancer cells were plated in 96-well plates (BD Biosciences) and treated with various concentrations of kinase inhibitors, either alone or in combination, for 48 hours. Cell viability was determined using the MTT assay. Synergistic effects were determined by using the Chou–Talalay method to calculate the combination index (CI; ref. 29).

**Flow-cytometric analysis**

Cells were harvested, washed with cold PBS, and processed for CD24 and CD44 surface markers. Allophycocyanin-conjugated anti-CD24 (BD Biosciences) and phycoerythrin-conjugated anti-CD44 (BD Biosciences) antibodies were used. To measure the levels of CD44⁺/CD24⁻/low cells, MDA-MB-231, MCF7, and BT20 cells stained with fluorescein isothiocyanate-conjugated anti-CD44 antibody and phycoerythrin-conjugated anti-CD24 antibody (both at 1:50) were sorted at the Flow Cytometry and Cellular Imaging Core Facility of The University of Texas MD Anderson Cancer Center (Houston, TX).

**Mouse studies**

All animal procedures were conducted under the guidelines approved by the Institutional Animal Care and Use Committee at MD Anderson Cancer Center. Athymic mice (Harlan Laboratories) were used as hosts for tumor xenografts. MDA-MB-231 cells with luciferase and GFP expression were used for tumor injection. Mice were divided according to the mean tumor volume in each group when the diameter of tumor size reached 4 mm. On the basis of our experience with in vitro tumorigenic analyses (Fig. 6A and B), we observed synergism when at least one single kinase inhibitor reached 50% of cell killing effect. To find synergistic effect in vivo, the doses of single-drug treatments were also chosen at 50% inhibition. The ED₅₀ (50% effective dose) of crizotinib and safingol was estimated by a dose-titration experiment (data not shown) and comparable with previous reports in other cancer cell lines (28, 29). Crizotinib was prepared by dissolving the drug in 50 mmol/L sodium acetate buffer (pH 4.6; ref. 30) and administered orally at 8 mg/kg every other day (31). L-threo-dihydro-sphingosine was prepared by dissolving the drug in 5% dextrose containing lactic acid, with pH adjusted to 4.4 (32), and was injected intravenously at 20 mg/kg twice a week (33). Tumors were measured twice weekly with a caliper, and tumor volume was calculated as (width² × length)/2. Tumor volume measured during drug treatment was normalized to the volume before treatment. The CI was calculated as survival rate(drugs A + B)/survival rate(drug A) × survival rate(drug B).

**Patient tissue samples**

The TNBC specimens (n = 107) used for our IHC and survival analyses were originally obtained from patients undergoing surgical resection of breast cancer as primary treatment at MD Anderson Cancer Center or Mackay Memorial Hospital (Taipei, Taiwan) between 1995 and 2009. The specimens were used in accordance with the protocols approved by the Institutional Review Board of MD Anderson Cancer Center. Written informed consent was obtained from patients in all cases at the time of resection.

**Results**

Eight TNBC-related kinases are commonly overexpressed in TNBC subtypes and BTIC populations

To identify cancer-related kinases that are overexpressed in TNBC and BTICs, we performed a two-stage bioinformatics analysis of both cell line data and patient data. The study design is outlined in Fig. 1A. The first stage was a cell-based analysis of data from two mRNA databases (14, 23) and two miRNA databases (34, 35) to identify oncogenes involved in TNBC. Breast cancer gene expression profile data were from the CCLE (23) and NCI-60 datasets (34), and BTIC gene
Figure 1. Thirteen druggable targets for aggressive TNBC were identified by bioinformatics analysis of TNBC and BTIC databases. A, schematic representation of the TNBC bioinformatics analysis. B, breast cancer cell lines were grouped by mRNA subtype according to ERBB2, ESR1, and PGR mRNA expression levels into non-TNBC (n = 30) and TNBC (n = 26) cells. The graph on the right was generated from original and log_{2}-transformed mRNA expression levels of TNBC-related kinases in breast cancer subtypes. Genes highly expressed in TNBC cells (ERBB2, ESR1, and PGR) are bold faced. The heatmap represents color-coded expression levels of differentially expressed genes in all breast cancer cell lines tested. The color scale ranges from saturated green for log ratios of −2.0 and below to saturated red for log ratios of 2.0 and above. C, twenty TNBC cell lines were subtyped according to previously published criteria (2), and six luminal breast cancer cell lines were selected as controls. The color scale ranges from saturated green for log ratios of −2.0 and below to saturated red for log ratios of 2.0 and above. The average expression levels of the 13 TNBC-related kinases are shown in the top row.
expression profile data were from isolated human breast tumors (14), a mammary epithelial cell line, and primary human mammalian epithelial cells (35), representing the heterogeneity of TNBC. We focused on cancer-related kinases, as they are ideal drug targets, and by filtering miRNA targets with the Ingenuity Pathway Analysis System, we identified 23 kinases that were predicted to be upregulated in BTICs and TNBC (Table 1). We then validated the mRNA expression patterns of these 23 kinases by hierarchical clustering of expression levels in 56 breast cancer cell lines (CCLE) and identified thirteen kinases that had higher expression in TNBC cell lines \( (n = 26) \) than in non-TNBC cell lines \( (n = 30; \text{Fig. 1B}) \).

To determine whether these thirteen kinases are associated with a specific TNBC subgroup, we examined their expression levels in 20 TNBC cell lines, including 10 basal-like, 8 mesenchymal-like, and 2 unclassified, according to previously published criteria (2). We found that the average expression levels of these thirteen kinases were elevated in one unclassified, six of ten basal-like, and all eight mesenchymal-like TNBC subtypes compared with expression levels in the luminal breast cancer subtype (Fig. 1C). The results indicated that mRNA expression levels of these 13 kinases are higher in most TNBCs tested, especially in the mesenchymal-like subtype.

To validate the above findings, we compared the mRNA and protein expression levels of the 13 kinases in breast cancer cell lines; among these, the mRNA expression levels of eight (CDK6, FYN, LYN, MET, PRKCA, RPS6KA3, MAP4K4, and PIK3CD) were significantly higher in at least two of four TNBC cell lines (BT549, Hs578T, MDA-MB-231, and MDA-MB-468) compared with expression levels in a non-TNBC cell line (T47D; Fig. 2A and Supplementary Fig. S1). Western blot analysis indicated that expression levels of MET, PKC-\( \alpha \) (from PRKCA), RSK-2 (from RPS6KA3), LYN, FYN, and CDK6 were higher in most of the six TNBC cell lines tested than in six non-TNBC cell lines (Fig. 2B). Although the levels of PIK3CD (which encodes PI3K \( \delta \)) and MAP4K4 mRNA were higher in TNBC cell lines than in non-TNBC cell lines, the protein expression levels were not. Generally, the protein levels of these kinases were overexpressed in most TNBC cell lines tested; therefore, they served as a basis for further experimental analysis.

To evaluate the expression levels of the eight kinases in BTICs, we isolated CD44\(^{+}/\text{CD24}^{–}\) /CD24\(^{+}/\text{CD44}^{–}\)stem cells from a TNBC cell line (BT20) by flow cytometry. CDK6, LYN, MAP4K4, MET, PIK3CD, PRKCA, and RPS6KA3 mRNA levels were upregulated in the isolated CD44\(^{+}/\text{CD24}^{–}\) /CD24\(^{+}/\text{CD44}^{–}\)subpopulations from TNBC cell line (BT20 cells; Fig. 2C) compared with the levels in CD44\(^{–}/\text{CD24}^{+}\) nonstem cells. Interestingly, FYN, LYN,
MAP4K4, PIK3CD, PRKCA, and RPS6KA3 mRNA levels were also upregulated in the isolated CD44^+/CD24^-/low subpopulations from the non-TNBC cell line (MCF7 cells; Fig. 2D), suggesting that the eight kinases are commonly overexpressed in BTICs. Because the increased expression of the eight kinases is likely an important feature of TNBC, we named them "TNBC-related kinases."

Expression of TNBC-related kinases correlates with TNBC clinical subtypes

The second stage of our bioinformatics analysis (Fig. 1A) was to determine whether the eight TNBC-related kinases correlated with TNBC clinical subtypes. We examined mRNA expression levels of the TNBC-related kinases in the data from TCGA breast invasive carcinoma patient cohort (16).
We used ERBB2, ESR1 (which encodes ER), and PGR (which encodes PR) gene expression patterns to distinguish TNBC patients from non-TNBC patients. The hierarchical clustering algorithm used is based closely on the average-linkage method, indicating that the mRNA expression levels of the eight TNBC-related kinases highly correlated with TNBC (Fig. 3A). Box plots were generated from the original log2-transformed mRNA expression levels of the eight kinases by breast cancer subtype on the basis of the mRNA expression levels of ESR1, PGR, and ERBB2. These findings indicate that expression of the TNBC-related kinases is strongly associated with TNBC versus non-TNBC (Fig. 3B). The histogram PNG files show how cutoffs were set based on unbiased and automatic K-Means algorithm for the separation of TNBC and non-TNBC tumors (Fig. 3C). Taken together, the results of both cell and patient database analyses suggest that TNBC-related kinases likely play important roles in the aggressive behavior of TNBC.

Overexpression of PRKCA, MET, and CDK6 correlates with poor prognosis in patients with TNBC

To identify the most suitable therapeutic targets among the eight TNBC-related kinases for TNBC, we analyzed the relationship between the TNBC-related kinases and overall survival in patients with breast cancer. Using an online Kaplan-Meier plotter (36), three out of the eight kinases (PRKCA, MET, and CDK6) that showed high expression were associated with shorter overall survival in patients with TNBC (P = 0.019, 0.02, and 0.073, respectively; Fig. 4A and data not shown) based on the univariate analysis with selected probes. Consistently, another data analysis from breast cancer cohort NKI-295 (28) with selected cutoffs also indicated that PRKCA, MET,

![Figure 3. Cluster analysis identified eight TNBC-related kinases overexpressed in TNBC from the TCGA breast invasive carcinoma patient cohort. A, hierarchical clustering analysis of eight TNBC-related kinases that distinguish TNBC from other human breast tumors (n = 753). Patients with breast cancer were categorized by mRNA subtype as non-TNBC patients (n = 613) and TNBC patients (n = 140) according to expression of ERBB2, ESR1, and PGR (encoding HER2, ER, and PR, respectively). The color scale ranges from saturated green for log ratios of −2.0 and below to saturated red for log ratios of 2.0 and above. Red represents high gene expression (>2), and green represents low gene expression (<2). B, box plot generated from original and log2-transformed mRNA expression levels of TNBC-related kinases in TNBC patients and non-TNBC patients by ESR1, PGR, and ERBB2 mRNA subtyping. C, data were clustered by the standard K-means clustering algorithm to separate ESR1-high and ESR1-low expression, and PGR-high and PGR-low expression tumors. Cutoffs were set automatically (indicated by red line).](https://example.com/figure3.png)
and CDK6 expression levels were correlated with worse overall survival ($P = 0.003$, 0.086, and 0.002, respectively; Fig. 4B). Furthermore, high expression of PRKCA/MET ($P = 0.018$), PRKCA/CDK6 ($P < 0.0001$), or CDK6/MET ($P = 0.005$) correlated with more adverse survival outcomes than each one alone in patients with breast cancer (Fig. 4C). Interestingly, the survival rates of patients with breast cancer in whom three kinases PRKCA/CDK6 were coexpressed were not worse than in whom two kinases were coexpressed (data not shown), providing a rationale to investigate whether the dual-drug combinations sufficiently impede TNBC progression. Together, these results suggest that expression of PRKCA, MET, or CDK6 has the potential to serve as a prognostic marker and therapeutic target for breast cancer, especially TNBC.
Dual-drug combinations of PKC-α, MET, and CDK6 inhibitors synergistically inhibit TNBC cell proliferation

Given that expression of two of the three kinases PKC-α, MET, and CDK6 was more highly correlated with patient survival than was expression of any one of the three kinases alone and that PRKCA/MET/CDK6 were not worse than in whom two kinases were coexpressed, we investigated the anti-TNBC efficacies of dual-drug combinations of safingol (a PKC-α and sphingosine kinase 1 inhibitor), crizotinib (a MET inhibitor), and PD0332991 (a CDK4/6 inhibitor)—drugs that either are in clinical trials or have been approved by the Food and Drug Administration (and therefore could be readily tested in combination in clinical trials). As shown in Fig. 5A, when two of the three kinase inhibitors were combined, the synergistic cytotoxic effects seemed to be higher in TNBC cells than in non-TNBC cells. In addition, normal epithelial cells (MCF10A) exhibited more resistance of all the dual-drug combinations under similar treatments conditions, suggesting that these dual-drug combinations preferentially kill TNBC cells over non-TNBC cancer cells or normal breast epithelial cells. To further demonstrate whether CSC population is more sensitive to the combination therapy, drug-treated MDA-MB-231 cells were subjected to FACS to determine the percentage of CD44+/CD24−/low population and assess the cells’ ability to form mammospheres. As shown in Supplementary Fig. S2A, MDA-MB-231 cells treated with DMSO contained 81 ± 5% CD44+/CD24−/low population, whereas those treated with combination of safingol–crizotinib, safingol–PD0332991, or crizotinib–PD0332991 contained significantly less (34 ± 12%, 24 ± 12%, or 26 ± 10%, respectively). In addition, all three combinations and single drug treatments caused a decrease in mammosphere formation (Supplementary Fig. S2B). Taken together, these findings support the notion that the stem-like MDA-MB-231 cells were more sensitive to these three dual-drug combinations than their non-stem like counterparts.

To further validate the synergistic killing effects of dual-drug combinations targeting PKC-α, MET, and CDK6, we carried out drug interaction analysis using the Chou–Talalay method to determine the CI (37). TNBC cells were treated with safingol, crizotinib, or PD0332991 alone or in combination (safingol plus crizotinib, safingol plus PD0332991, or crizotinib plus PD0332991) at various concentrations. The CIs of the dual drug combinations are shown in Fig. 5B; CI values of <1, 1, and >1 indicate that the two drugs in the combination have synergistic, additive, or antagonistic effects, respectively. All three dual-drug combinations synergistically inhibited TNBC cell proliferation, especially at the highest EDs, which killed most cancer cells. The greatest synergism (CI) for the safingol–crizotinib combination was observed in MDA-MB-231 and BT549 cells at 95% EDs with CI values of 0.35 and 0.15, respectively. However, for the crizotinib-PD0332991 combination, the greatest synergism observed in MDA-MB-231 and Hs578T cells was only at 50% EDs with CI values of 0.39 and 0.53, respectively (Table 2). According to these results, the combination with the best therapeutic effect was safingol–crizotinib with the strongest synergism, followed by safingol–PD0332991 and crizotinib–PD0332991 in that order. Interestingly, the safingol–crizotinib combination treatment also showed a slight synergism in non-TNBC cancer cells (0.82 at 95% EDs in T47D cells) and strong antagonistic effect in normal epithelial cells. These findings further indicate that these dual-drug combinations, especially safingol–crizotinib, may be effective against TNBC progression.

Combined inhibition of PKC-α and MET suppresses TNBC tumorigenesis in vitro and in vivo

Next, we examined the effects of the dual drug combinations on the tumorigenic potential of TNBC cells. All three combinations efficiently inhibited colony-forming ability in BT549 cells (Fig. 6A). Safingol combined with crizotinib or PD0332991 suppressed anchorage-independent colony formation more efficiently than did any one of the drugs by itself in both MDA-MB-231 and BT549 cells (Fig. 6B). However, crizotinib combined with PD0332991 did not inhibit anchorage-independent growth more efficiently than PD0332991 alone; suggesting that inhibition of PKC-α activity is required for optimal killing of TNBC cells. Indeed, PKC-α was recently identified as a central signaling node in non-CSC to CSC transformation and has been proposed as a potential therapeutic target for breast cancer (38). We further examined PKC-α expression and patient outcomes with a TNBC tissue microarray by IHC analysis, with results indicating that the survival rate was worse in patients with TNBC with high levels of PKC-α expression than those with low levels (P = 0.045; Fig. 6C). Collectively, our findings suggest that PKC-α is a unique prognostic indicator of TNBC patient survival.

Given that the safingol–crizotinib combination consistently showed synergistic killing effect from multiple in vitro assays, we further evaluated the efficacy of the safingol–crizotinib combination in a TNBC orthotopic xenograft mouse model. In agreement with results from our in vitro assays, the safingol–crizotinib combination was more effective in reducing tumor growth than was either single-drug treatment or vehicle control treatment (Fig. 6D). The inhibition efficiency in mice was 68% for the combination (CI = 0.43) but only 6% (P = 0.006) and 21% (P = 0.002) for safingol alone and crizotinib alone, respectively. We did not observe any significant body weight changes when mice were treated with the safingol or crizotinib alone or in combination (Fig. 6E). These results suggest that the dual-drug combination of PKC-α with MET may be effective against TNBC and could be readily applied for marker-guided clinical trials as inhibitors of the TNBC-related kinases are available in clinical trials or have been approved by FDA.

Discussion

Our analysis with multiple cell line and patient databases identified eight TNBC-related kinases—MET, FYN, PKC-α, MAP4K4, LYN, PI3K δ, CDK6, and RSK-2—that are commonly overexpressed in TNBC/BTCIs. Of these eight kinases, PKC-α, MET, and CDK6 associated with the worst survival outcomes in patients with breast cancer. Dual-drug combinations that target these three kinases synergistically inhibited TNBC cell proliferation and in vitro tumorigenic
potential. The combination that showed the strongest synergism (PKC-α and MET inhibition) also synergistically (CI = 0.43; Fig. 6D) attenuated tumor growth in vivo. Our findings suggest that combining drugs already in use may accelerate the availability of marker-guided therapy for TNBC.

Currently, the most promising clinical target for TNBC is the enzyme PARP, a member of the family of nuclear enzymes.
involved in the detection and repair of DNA damage (39). There are at least five PARP inhibitors that are in clinical trials, and among them, BSI-201 (iniparib; ref. 40) and AZD2281 (olaparib; ref. 41) have been evaluated in multiple clinical trials in women with metastatic breast cancer. However, the results indicated that the reduced rate of tumor regression was observed mostly in patients with the \textit{BRCA1} or \textit{BRCA2} mutations (42). Thus, efficacy of PARP inhibitors in patients with TNBC is still nuclear (43). Recent encouraging data showed that inhibition of PI3K impairs DNA homologous recombination and sensitizes TNBC without \textit{BRCA} mutations to poly(ADP-ribose) inhibition (44). However, this mechanism has yet to be tested in patients, and important questions remain unanswered.

TNBC is the most heterogeneous subtype of breast cancer, and because no individual cell line represents the heterogeneity of TNBC, it is difficult to find an appropriate TNBC model. The well-established cell-based systems, such as the BPLER cancer cell line derived from human primary breast epithelial cells, have a TNBC-like phenotype \textit{in vitro} and are highly enriched for BTICs (45). Although BPLER mimics TNBC, this system is most appropriate for the basal-like TNBC subtype, which accounts for about half of the TNBC cases (46). In identifying 13 TNBC-related kinases that are expressed in most TNBC subtypes (Fig. 1C), including the basal-like and mesenchymal-like subtypes, our study overcame some of the limitations associated with TNBC heterogeneity.

In the absence of major growth stimulation on their surface, TNBC cells may rely on downstream signaling to compensate for the loss of cell-surface signaling to support cell growth. Kinases are ideal target molecules, as they transmit signals, control complex cellular processes, and are frequently activated in cancer by mutation, constitutive activation, or overexpression. A gene expression profiling study of 102 human breast tumors identified several kinases as druggable targets in ER-negative breast cancer (47). The identification of \textit{LYN}, MAP4K4, \textit{MET}, and \textit{RPS6KA3} kinases in both that study and ours suggests that these kinases are common regulators in TNBC. We further showed that dual-drug combinations using PKC-\(\alpha\), CDK6, and \textit{MET} kinase inhibitors enhanced the killing on TNBC cells, reduced the tumorigenic phenotype \textit{in vitro}, and synergistically impeded tumor growth \textit{in vivo}. These results further attest to the critical role these kinases play in transmitting oncogenic signaling in TNBC. It may be worthwhile to test the efficacy of other dual-drug

### Table 2. CIs of dual-drug combinations in different breast cancer cells

<table>
<thead>
<tr>
<th>Drug combination</th>
<th>CI</th>
<th>ED&lt;sub&gt;50&lt;/sub&gt;</th>
<th>ED&lt;sub&gt;75&lt;/sub&gt;</th>
<th>ED&lt;sub&gt;90&lt;/sub&gt;</th>
<th>ED&lt;sub&gt;95&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-231</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>1.00</td>
<td>0.66</td>
<td>0.44</td>
<td>0.35</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>1.03</td>
<td>0.70</td>
<td>0.57</td>
<td>0.57</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>0.39</td>
<td>0.76</td>
<td>1.72</td>
<td>3.27</td>
<td></td>
</tr>
<tr>
<td>BT549</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>1.96</td>
<td>0.68</td>
<td>0.27</td>
<td>0.15</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>0.81</td>
<td>0.74</td>
<td>0.70</td>
<td>0.69</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>1.11</td>
<td>1.02</td>
<td>0.94</td>
<td>0.89</td>
<td></td>
</tr>
<tr>
<td>Hs578T</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>0.52</td>
<td>0.60</td>
<td>0.71</td>
<td>0.79</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>0.58</td>
<td>0.79</td>
<td>1.17</td>
<td>1.56</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>0.53</td>
<td>1.26</td>
<td>3.20</td>
<td>6.05</td>
<td></td>
</tr>
<tr>
<td>SK-BR-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>1.23</td>
<td>1.07</td>
<td>0.93</td>
<td>0.84</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>1.20</td>
<td>1.25</td>
<td>1.30</td>
<td>1.34</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>1.55</td>
<td>1.45</td>
<td>1.36</td>
<td>1.31</td>
<td></td>
</tr>
<tr>
<td>T47D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>0.99</td>
<td>0.90</td>
<td>0.85</td>
<td>0.82</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>1.04</td>
<td>0.99</td>
<td>1.06</td>
<td>1.15</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>1.11</td>
<td>1.18</td>
<td>1.26</td>
<td>1.32</td>
<td></td>
</tr>
<tr>
<td>MCF10A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sa-Cr</td>
<td>3.03</td>
<td>13.10</td>
<td>59.89</td>
<td>168.96</td>
<td></td>
</tr>
<tr>
<td>Sa-PD</td>
<td>1.42</td>
<td>1.20</td>
<td>1.04</td>
<td>0.96</td>
<td></td>
</tr>
<tr>
<td>Cr-PD</td>
<td>1.22</td>
<td>1.09</td>
<td>1.01</td>
<td>0.98</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: TNBC cells (MDA-MB-231, BT549, and Hs578T), non-TNBC cells (T47D and SK-BR-3), and normal epithelial cells (MCF10A) were used to determine the CI index of safingol (Sa), crizotinib (Cr), and PD0332991 (PD) in dual-drug combinations. CIs of \(<1\), \(1\), and \(>1\) indicate synergism, additive effect, and antagonism, respectively. CI index \(<0.9\) is labeled in bold.
in human breast cell lines and tumors was significantly higher levels of PKC-α.

PKC-α expression in human breast tumor tissue was significantly higher in ER-negative tumors than in ER-positive tumors. PKC-α overexpression has also been suggested to have a role in growth signaling when breast cancer cells shift from hormone dependence to hormone independence.

An inverse relationship between PKC-α activity and ER expression was established in human breast cell lines and tumors in prolonging survival. Cisplatin (Cr; 0.75 μmol/L), crizotinib (Sa; 0.75 μmol/L), and PD0332991 (PD; 0.75 μmol/L) separately or in combination for 10 days. The number of colony-forming cells was determined by clonogenic assay in BT549. Cells were treated with cisplatin (0.5 μmol/L), crizotinib (0.5 μmol/L), and PD0332991 (0.2 μmol/L) separately or in combination, for 21 days. Representative images from the clonogenic and anchorage-independent growth assays (carried out as described in Materials and Methods) are shown. The data on the right are means with SDs for three independent experiments. *P < 0.05 for differences between combination and single-drug treatments. Representative images of IHC staining of PKC-α expression in human TNBC tissues (left). TNBC tissue microarray analysis of overall survival in PKC-α-overexpressing patients. To ensure objectivity, the ACIS III automated cellular imaging system (Dako) was used for tissue scoring and quantification. All correlations between kinase expression levels were analyzed using SPSS version 15.0 statistical software (right). The overall survival durations after surgery were analyzed using a Kaplan–Meier plot. The Cox proportional hazards regression model was used to assess prognostic factors for overall survival. Cumulative, cumulative. Survival rate is shown by Kaplan–Meier survival curves. The effect of the dual-drug combination of PKC-α, MET, and CDK6 inhibitors synergistically suppressed clonogenic and anchorage-independent growth in vitro and in an animal model.

Dual-drug combinations of PKC-α, MET, and CDK6 inhibitors synergistically suppressed clonogenic and anchorage-independent growth in vitro and in an animal model. A, the number of colony-forming cells was determined by clonogenic assay in BT549. Cells were treated with cisplatin (Sa; 0.75 μmol/L), crizotinib (Cr; 0.75 μmol/L), and PD0332991 (PD; 0.75 μmol/L) separately or in combination, for 10 days. B, the number of colony-forming cells was determined by clonogenic-independent growth analysis in MDA-MB-231 and BT549 cells. Cells were treated with cisplatin (0.5 μmol/L), crizotinib (0.5 μmol/L), and PD0332991 (0.2 μmol/L) separately or in combination, for 21 days. Representative images from the clonogenic and anchorage-independent growth assays (carried out as described in Materials and Methods) are shown. The data on the right are means with SDs for three independent experiments. *P < 0.05 for differences between combination and single-drug treatments. C, representative images of IHC staining of PKC-α expression in human TNBC tissues (left). TNBC tissue microarray analysis of overall survival in PKC-α-overexpressing patients. To ensure objectivity, the ACIS III automated cellular imaging system (Dako) was used for tissue scoring and quantification. All correlations between kinase expression levels were analyzed using SPSS version 15.0 statistical software (right). The overall survival durations after surgery were analyzed using a Kaplan–Meier plot. The Cox proportional hazards regression model was used to assess prognostic factors for overall survival. Cumulative, cumulative. Survival rate is shown by Kaplan–Meier survival curves. The effect of the dual-drug combination of PKC-α, MET, and CDK6 inhibitors synergistically suppressed clonogenic and anchorage-independent growth in vitro and in an animal model. A, the number of colony-forming cells was determined by clonogenic assay in BT549. Cells were treated with cisplatin (Sa; 0.75 μmol/L), crizotinib (Cr; 0.75 μmol/L), and PD0332991 (PD; 0.75 μmol/L) separately or in combination, for 10 days. B, the number of colony-forming cells was determined by clonogenic-independent growth analysis in MDA-MB-231 and BT549 cells. Cells were treated with cisplatin (0.5 μmol/L), crizotinib (0.5 μmol/L), and PD0332991 (0.2 μmol/L) separately or in combination, for 21 days. Representative images from the clonogenic and anchorage-independent growth assays (carried out as described in Materials and Methods) are shown. The data on the right are means with SDs for three independent experiments. *P < 0.05 for differences between combination and single-drug treatments. C, representative images of IHC staining of PKC-α expression in human TNBC tissues (left). TNBC tissue microarray analysis of overall survival in PKC-α-overexpressing patients. To ensure objectivity, the ACIS III automated cellular imaging system (Dako) was used for tissue scoring and quantification. All correlations between kinase expression levels were analyzed using SPSS version 15.0 statistical software (right). The overall survival durations after surgery were analyzed using a Kaplan–Meier plot. The Cox proportional hazards regression model was used to assess prognostic factors for overall survival. Cumulative, cumulative. Survival rate is shown by Kaplan–Meier survival curves. The effect of the dual-drug combination of PKC-α, MET, and CDK6 inhibitors synergistically suppressed clonogenic and anchorage-independent growth in vitro and in an animal model.
Tauf Therapeutics, Critical Outcome Technologies, HanAlBio Korea, Nuevolution, Pfizer, Provista Diagnostics, Roche, Signalchem Lifesciences, and Symphogen. No potential conflicts of interest were disclosed by the other authors.

**Authors' Contributions**

Conception and design: Y.-H. Hsu, T.-J. Wu, W.-C. Huang, C.-L. Liu, M.-Y. Wang, A.A. Sahin, M.-C. Hung

Development of methodology: Y.-H. Hsu, L.-C. Chan, G.B. Mills

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y.-H. Hsu, L.-C. Chan, Y.-F. Fang, Y. Wu, C.-L. Liu, M.-Y. Wang, M.-K. Chen, D. Yu

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y.-H. Hsu, J. Yao, L.-C. Chan, T.-J. Wu, Y. Wei, A.A. Sahin, A. Sood, G.B. Mills, G.N. Hortobagyi, M.-C. Hung

Writing, review, and/or revision of the manuscript: Y.-H. Hsu, J. Yao, J.L. Hsu, A. Sood, G.B. Mills, D. Yu, G.N. Hortobagyi, M.-C. Hung

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y.-H. Hsu, T.-J. Wu, W.-C. Huang, Y.-C. Chang, J. Shen, M.-K. Chen, G.B. Mills, G.N. Hortobagyi, M.-C. Hung

Study supervision: Y.-H. Hsu, W.-C. Huang, C.-W. Li, M.-C. Hung

Other (discussed the project with the first author): D. Yu

**Acknowledgments**

The authors thank Arthur Gelmis from Scientific Publications at MD Anderson for editing the article and Su Zhang, Qian Guan Shi, Zhenbo Han, Jin-Fong Lee, and Junyan Wang for technical assistance. STR DNA fingerprinting was performed at the Cancer Center Support Grant-funded Charac-te rized Cell Line Core Facility of MD Anderson Cancer Center (NICI grant CA016672). In memorial, Mr. Tsong Lii Ang for his courageous fight against cancer.

**Grant Support**

This work was funded, in part by, the NIH (grants CA109311, CA099031, and CCSR CA16672), the National Breast Cancer Foundation, Inc., the Breast Cancer Research Foundation. The University of Texas MD Anderson-China Medical University, and Hospital Sister Institution Fund (M.-C. Hung), the Ministry of Health and Welfare, China Medical University Hospital Cancer Research Center of Excellence (MOHIV103-TD-B-111-03; Taiwan), the Program for Stem Cell and Regenerative Medicine Frontier Research (NSC 102-2321-B-039-001; Taiwan), the International Research-Intensive Centers of Excellence in Taiwan (NSC 101- 2911-i-003-002), and the Center for Biological Pathways, Postdoctoral Research Ablorad Program (grant 101P9999900059 from the National Science Council of Taiwan; T.-H. Hsu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 28, 2014; revised May 20, 2014; accepted May 27, 2014; published OnlineFirst June 26, 2014.

**References**

Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer

Yi-Hsin Hsu, Jun Yao, Li-Chuan Chan, et al.

Cancer Res  Published OnlineFirst June 26, 2014.

Updated version Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-14-0584

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2014/06/27/0008-5472.CAN-14-0584.DC1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.